Updates are available Correction dated 2024-12-05
Click to view Correction: https://doi.org/10.1007/s12325-024-03010-9
-
Authors
Simpson, Eric https://orcid.org/0000-0003-0853-0252
Fernández-Peñas, Pablo
de Bruin-Weller, Marjolein
Lio, Peter A.
Chu, Chia-Yu
Ezzedine, Khaled
Agell, Helena
Casillas, Marta
Ding, Yuxin
Yang, Fan Emily
Pierce, Evangeline
Bieber, Thomas
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04146363 at ClinicalTrials.govnct04178967 at ClinicalTrials.govDocuments that mention this clinical trial
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01199-9
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
https://doi.org/10.1136/bmjopen-2025-102155
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
https://doi.org/10.1007/s12325-024-02974-y
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Documents that mention this clinical trial
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol
https://doi.org/10.1136/bmjopen-2025-102155
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
https://doi.org/10.1007/s12325-024-02974-y
- License Information
-
More Information
Article History
Received: 2 July 2024
Accepted: 15 August 2024
First Online: 9 September 2024
Change Date: 5 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12325-024-03010-9
Declarations
:
: Eric Simpson has received grants from or serves as Principal Investigator for: AbbVie, Amgen, Arcutis, ASLAN Pharmaceuticals, Castle Biosciences, CorEvitas, Dermavant, Dermira, Inc., Eli Lilly and Company, Incyte Corporation, Kymab, Kyowa Hakko Kirin, LEO Pharma, Pfizer, Regeneron, Sanofi, and Target RWE; and has received personal fees from: AbbVie, Amgen, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Boston Consulting Group, Collective Acumen, Dermira, Inc., Eli Lilly and Company, Evidera, Excerpta Medica, ForteBio, Galderma, GlaxoSmithKline, Incyte Corporation, Janssen, Kyowa Kirin, LEO Pharma, Medscape, Merck, Pfizer, Physicians World, Regeneron, Roivant Sciences, Sanofi Genzyme, Trevi Therapeutics, Valeant Pharmaceuticals, and WebMD; Pablo Fernández-Peñas has served on advisory boards for: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squib, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, Merck Sharp & Dohme, Novartis, Roche, Sanofi, and Sun Pharma; has given educational lectures for: AbbVie, Amgen, Avène, Eli Lilly and Company, Galderma, Janssen, La Roche-Posay, LEO Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Schering-Plough, Sun Pharma, and UCB Pharma; has conducted clinical trials for: AbbVie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, Dermira, Eisai, Eli Lilly and Company, Galderma, GlaxoSmithKline, Janssen, Jiangsu Hengrui Pharmaceuticals, Kyowa Hakko Kirin, LEO Pharma, miRagen, Novartis, OncoSec, Pfizer, Regeneron, Roche, Sun Pharma, UCB Pharma, and XOMA Corporation; Marjolein de Bruin-Weller has served as a consultant, speaker, advisor, and/or advisory board member for: AbbVie, Almirall, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Pfizer, Regeneron, and Sanofi Genzyme; Peter A. Lio has received grants as an investigator, honoraria for lecturing, and/or consulting fees from: AbbVie, AOBiome, Arbonne, Burt’s Bees, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Franklin BioScience/Altus Labs, Incyte Corporation, IntraDerm, Johnson & Johnson, Kiniksa Pharmaceuticals, La Roche-Posay/L’Oréal, LEO Pharma, Menlo Therapeutics, National Eczema Association, Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB Pharma, Unilever, and Verrica Pharmaceuticals; Chia-Yu Chu is an investigator, consultant, speaker, and/or advisory board member for: AbbVie, Amgen, Dermira, Eli Lilly and Company, GlaxoSmithKline, Janssen, Mylan, Novartis, Oneness Biotech, Pfizer, Regeneron, Roche, Sanofi, United BioPharma, and Viatris; Khaled Ezzedine is a consultant for AbbVie, Incyte, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi, Eli Lilly and Company, and Almirall; Helena Agell is an employee of: Almirall, S.A.; Marta Casillas, Yuxin Ding, Fan Emily Yang, and Evangeline Pierce are employees and shareholders of: Eli Lilly and Company; Thomas Bieber is a speaker, consultant, and/or investigator for: AbbVie, Affibody, Almirall, AnaptysBio, Arena Pharmaceuticals, Asana BioSciences, ASLAN Pharmaceuticals, Bayer Pharmaceuticals, BioVersys, Boehringer Ingelheim, Bristol-Myers Squibb, Connect Biopharma, Dermavant, Domain Therapeutics, Eli Lilly and Company, EQRx, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Incyte Corporation, Innovaderm Research, IQVIA, Janssen, Kymab, Kyowa Kirin, L’Oréal, LEO Pharma, LG Chem, Merck Sharp & Dohme, Novartis, Numab, OM Pharma, Pfizer, Pierre Fabre, Q32 Bio, RAPT Therapeutics, Sanofi Regeneron, and UCB Pharma; and is Founder and Chairman of the Board of the non-profit biotech: Davos Biosciences. Dr. Bieber was affiliated with University Hospital Bonn, Bonn, Germany at the time of the study and is currently affiliated with Medicine Campus, Davos, Switzerland.
: Both trials were approved by the appropriate ethics review boards across approximately 100 study sites in the United States, Canada, Europe, and the Asia–Pacific area and were performed in accordance with the ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent to participate in the trials. Patients provided written consent for use of their photographs for publication.
